Recent research reveals intriguing results concerning the role of exogenous lactate and the ketone body 3-hydroxybutyrate (3-OHB) as therapeutic tools to combat obesity and related conditions. Thus, oral administration of lactate and 3-OHB have separately been shown to suppress appetite sensations and slow gastric emptying while administered orally. Both seem to inhibit lipolysis while oral 3-OHB administration have shown direct insulin sensitizing effects. Furthermore, both substrates can be used as fuel for the heart. The goal of this placebo-controlled randomized crossover design is to test exogenous lactate and the ketone body 3-hydroxybutyrate (3-OHB) in healthy, non-diabetic, obese adults. The main questions it aims to answer are if chronic administration of LaKe ester affect or improve the following endpoints: * Insulin sensitivity * Appetite sensations * Gastric emptying * Lipolysis * Cardiac output * Left Ventricular Ejection Fraction * Global Longitudinal Strain and other echocardiographic measures listed below Participants will ingest a combined lactate and ketone body ester (LaKe ester) or placebo twice a day for 28 days before experimental days.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Insulin sensitivity expressed as an M-value
Timeframe: Throughout the cross-over design, approximately 12 weeks